Accounts Receivable turnover ratio remained unchanged during the first quarter 2024, compared to the previous quarter at 1.64 pointing to a challenging and on top of that deteriorating business climate for the Major Pharmaceutical Preparations industry. Average collection period, for Intelgenx Technologies 's accounts receivable remained unchanged at 223 days, in the Mar 31 2024 quarter.

If we take a look into Healthcare sector 537 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Mar 31 2024 from 3138 to 3430.

What is Receivable Turnover Ratio?
What is Intelgenx Technologies Corp Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

IGXT Receivables Turnover Ratio	(Mar 31 2024) I. Quarter	(Dec 31 2023) IV. Quarter	(Sep 30 2023) III. Quarter	(Jun 30 2023) II. Quarter	(Mar 31 2023) I. Quarter
Y / Y Receivable Change	4.75 %	-12.27 %	2.89 %	18.71 %	-21.75 %
Y / Y Revenue Change	7.41 %	141.04 %	123.94 %	-66.58 %	-31.65 %
Receivable Turnover Ratio (TTM)	1.64	1.64	1.21	0.94	1.41
IGXT's Total Ranking	# 3430	# 3138	# 3487	# 3044	#
Accounts Receivable average collection period days	223	223	302	387	258
Seq. Receivable Change	-0.64 %	2.64 %	-13.18 %	18.31 %	-16.78 %
Seq. Revenue Change	-58.27 %	31.13 %	139.1 %	-17.9 %	-6.36 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 192
Healthcare Sector	# 538
Overall Market	# 3430

Receivable Turnover Ratio Statistics
High	Average	Low
17.96	5.79	1.08
(Sep. 30, 2014)		(Jun 30 2020)

IGXT Company Profile • Back to IGXT Efficiency Comparisons • Compare IGXT Receivables Turnover Ratio to its Competitors

Financial Statements
Intelgenx Technologies 's Accounts Receivable	$ 1 Millions	Visit IGXT's Balance sheet
Intelgenx Technologies 's Sales TTM	$ 1 Millions	Visit IGXT's Income Statement
Sources of IGXT's Revenues		Visit IGXT's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
IGXT's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
IGXT's Growth Rates	IGXT's Roa	IGXT's Inventory Turnover Ratio	IGXT's Dividend Comparisons
IGXT's Profitability Ratios	IGXT's Roi	IGXT's Asset Turnover Ratio	IGXT's Dividend Growth
IGXT's Valuation Ratios	IGXT's Roe	IGXT's Financial Strength Ratios	IGXT's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Mar 31 2024, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Mar 31 2024	Receivable at quarter ending Mar 31 2024
Intra cellular Therapies Inc	4.63	$ 513.930 Millions	$ 110.952 Millions
Butterfly Network Inc	4.61	$ 67.656 Millions	$ 14.690 Millions
Dyadic International Inc	4.58	$ 2.255 Millions	$ 0.492 Millions
Liquidia Corporation	4.54	$ 15.967 Millions	$ 3.516 Millions
Amgen Inc	4.54	$ 29,532.000 Millions	$ 6,504.750 Millions
Avanos Medical Inc	4.53	$ 646.800 Millions	$ 142.900 Millions
Adaptimmune Therapeutics Plc	4.52	$ 18.358 Millions	$ 4.060 Millions
Orthopediatrics Corp	4.52	$ 160.839 Millions	$ 35.597 Millions
Igc Pharma Inc	4.51	$ 1.345 Millions	$ 0.299 Millions
Anaptysbio Inc	4.50	$ 22.962 Millions	$ 5.098 Millions
Xeris Biopharma Holdings Inc	4.49	$ 171.356 Millions	$ 38.201 Millions
Natera Inc	4.47	$ 1,208.556 Millions	$ 270.562 Millions
Reshape Lifesciences Inc	4.46	$ 8.205 Millions	$ 1.838 Millions
Vericel Corporation	4.46	$ 207.780 Millions	$ 46.585 Millions
Dermtech Inc	4.40	$ 13.817 Millions	$ 3.138 Millions
Caremax Inc	4.40	$ 577.579 Millions	$ 131.240 Millions
Scpharmaceuticals Inc	4.40	$ 17.632 Millions	$ 4.012 Millions
Exagen Inc	4.39	$ 55.733 Millions	$ 12.683 Millions
Karyopharm Therapeutics Inc	4.38	$ 140.461 Millions	$ 32.062 Millions
Celularity Inc	4.36	$ 33.517 Millions	$ 7.685 Millions
Bristol myers Squibb Company	4.36	$ 45,534.000 Millions	$ 10,446.000 Millions
Dexcom Inc	4.36	$ 3,801.300 Millions	$ 872.200 Millions
Healthcare Services Group Inc	4.36	$ 1,677.592 Millions	$ 385.153 Millions
Bioxcel Therapeutics Inc	4.35	$ 1.756 Millions	$ 0.404 Millions
Bioventus Inc	4.35	$ 522.654 Millions	$ 120.216 Millions
Mirum Pharmaceuticals Inc	4.35	$ 223.998 Millions	$ 51.532 Millions
Bionano Genomics Inc	4.34	$ 37.470 Millions	$ 8.639 Millions
Werewolf Therapeutics Inc	4.34	$ 16.221 Millions	$ 3.741 Millions
Elite Pharmaceuticals Inc	4.32	$ 56.357 Millions	$ 13.040 Millions
Celldex Therapeutics inc	4.28	$ 6.072 Millions	$ 1.417 Millions

Date modified: 2026-08-29T17:27:21+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.